All posts

Follow Us

LinkedInInstagramX
Quarterly ResultsArchiveLast updated 22 November 20263 min read

KMS Medisurgi (KMSMEDI) Q2 FY27 Posts Q2 Loss as Costs Outpace Sales Recovery

The surgical equipment maker saw a quarterly loss of ₹0.22 crore as higher employee costs and depreciation squeezed margins, with auditors flagging accounting issues.

By Anant Kacholia, HexaWealth Research · Created 17 November 2026

KMS Medisurgi reported a net loss of ₹0.22 crore for Q2 FY27, a sharp reversal from a profit a year ago. Revenue fell 6.8% YoY to ₹6.17 crore, while total expenses rose, compressing margins. The company's auditor raised concerns over employee benefits and stock valuation.

For a small surgical equipment maker, the challenge is balancing investment in new capacity with the reality of current demand. KMS Medisurgi's second quarter shows that tension clearly, as a modest sales recovery was overwhelmed by rising fixed costs and accounting uncertainties.

The numbers tell a story of pressure on both ends. Revenue of ₹6.17 crore was down 6.8% from a year earlier, though it improved 10.4% sequentially. The bottom line swung to a loss of ₹0.22 crore, a stark contrast to the ₹0.23 crore profit in Q2 FY26. This pushed the net profit margin to -3.6%.

Revenue & profit

Revenue (₹ Cr)

Profit (₹ Cr)

Revenue & profitQ2 FY25 7.81, Q4 FY25 6.12, Q2 FY26 6.62, Q4 FY26 5.59, Q2 FY27 6.17. Q2 FY25 0.08, Q4 FY25 0.36, Q2 FY26 0.23, Q4 FY26 0.01, Q2 FY27 -0.22-20-1001020Q2 '25Q4 '25Q2 '26Q4 '26Q2 '27
  • Revenue (₹ Cr), Q2 FY25: 7.81
  • Revenue (₹ Cr), Q4 FY25: 6.12
  • Revenue (₹ Cr), Q2 FY26: 6.62
  • Revenue (₹ Cr), Q4 FY26: 5.59
  • Revenue (₹ Cr), Q2 FY27: 6.17
  • Profit (₹ Cr), Q2 FY25: 0.08
  • Profit (₹ Cr), Q4 FY25: 0.36
  • Profit (₹ Cr), Q2 FY26: 0.23
  • Profit (₹ Cr), Q4 FY26: 0.01
  • Profit (₹ Cr), Q2 FY27: -0.22

Revenue (₹ Cr)

Revenue (₹ Cr)Q2 FY25 7.81, Q4 FY25 6.12, Q2 FY26 6.62, Q4 FY26 5.59, Q2 FY27 6.1705101520Q2 '25Q4 '25Q2 '26Q4 '26Q2 '27
  • Revenue (₹ Cr), Q2 FY25: 7.81
  • Revenue (₹ Cr), Q4 FY25: 6.12
  • Revenue (₹ Cr), Q2 FY26: 6.62
  • Revenue (₹ Cr), Q4 FY26: 5.59
  • Revenue (₹ Cr), Q2 FY27: 6.17

Profit (₹ Cr)

Profit (₹ Cr)Q2 FY25 0.08, Q4 FY25 0.36, Q2 FY26 0.23, Q4 FY26 0.01, Q2 FY27 -0.22-2-1012Q2 '25Q4 '25Q2 '26Q4 '26Q2 '27
  • Profit (₹ Cr), Q2 FY25: 0.08
  • Profit (₹ Cr), Q4 FY25: 0.36
  • Profit (₹ Cr), Q2 FY26: 0.23
  • Profit (₹ Cr), Q4 FY26: 0.01
  • Profit (₹ Cr), Q2 FY27: -0.22

Net Profit Margin (%)

Net Profit Margin (%)Q2 FY25 1.0, Q4 FY25 5.9, Q2 FY26 3.5, Q4 FY26 0.2, Q2 FY27 -3.6-8%-4%0%4%8%Q2 '25Q4 '25Q2 '26Q4 '26Q2 '27
  • Net Profit Margin (%), Q2 FY25: 1.0
  • Net Profit Margin (%), Q4 FY25: 5.9
  • Net Profit Margin (%), Q2 FY26: 3.5
  • Net Profit Margin (%), Q4 FY26: 0.2
  • Net Profit Margin (%), Q2 FY27: -3.6
MetricCurrentQ2 FY27Same quarter LYQ2 FY26
Revenue (₹ Cr)
6.17YoY -6.8%
6.62
Profit (₹ Cr)
-0.22YoY -196%
0.23
Net Profit Margin (%)
-3.6YoY -203%
3.5

The Cost of Unused Capacity

The primary driver of the loss was a 16.1% quarter-on-quarter jump in total expenses, far outpacing the 10.4% revenue increase. Research from Scanx.trade points to a significant rise in depreciation, up 77% in FY26 due to capital additions of ₹1.72 crore in plant and machinery. This suggests the company is bearing the cost of a new coating line, commissioned last year, before it has generated meaningful sales growth.

Employee costs also rose, adding to the margin squeeze. Meanwhile, the company's auditor, H H Dedhia & Associates, qualified its review report. As noted by ForgeUp and Stockwatch.live, the auditor flagged a departure from accounting standards on post-employment benefits and could not ascertain the value of closing stock pending reconciliation.

A Market Awash with Imports

The revenue decline points to a tough competitive environment. India's medical device market remains heavily import-dependent, with low-cost products from ASEAN nations creating pricing pressure. This backdrop makes it difficult for small domestic manufacturers like KMS Medisurgi to gain traction, even with new capacity.

Live Chart

· KMSMEDI

(BSE)

ISIN: INE870V01014

Management has not provided specific FY27 guidance, but the market reaction was clear. Analysis from MCapital categorized the results as having a 'very negative' impact, noting the stock fell nearly 5% following the announcement. The absence of institutional investors, with promoters holding 74.42% of the stake, leaves the stock exposed to sharp moves on operational setbacks.

Key Points

  • KMS Medisurgi reported a net loss of ₹0.22 crore in Q2 FY27, as a 6.8% YoY revenue decline combined with sharply higher expenses.
  • The loss was driven by increased depreciation from recent capital expenditure and rising employee costs, compressing the net profit margin to -3.6%.
  • The company's auditor raised qualifications concerning accounting for employee benefits and an inability to verify closing stock value.
  • The stock fell nearly 5% post-results, reflecting a negative market view on the weak operational performance and auditor concerns.

Hexa Perspective

The quarter underscores the operational risk of expanding capacity ahead of demand. The new coating line, intended to nearly double output, is now a fixed cost drag with sales yet to respond. The auditor's qualifications add a layer of financial reporting uncertainty that investors typically discount heavily.

The path forward hinges on utilizing that new capacity. The company's plan to launch adhesive tapes for automotive and electrical uses, mentioned in its annual report, remains a concept without a confirmed launch or customer. Until sales can rise to absorb the higher depreciation, profitability will remain under pressure. For now, the story is one of investment waiting for a market answer.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

KMS Medisurgi (KMSMEDI) Q2 FY27 results, revenue and profits.

Frequently asked questions

What were KMS Medisurgi's Q2 FY27 results?
KMS Medisurgi reported a net loss of ₹0.22 crore for Q2 FY27 (quarter ended September 2026). Revenue declined 6.8% year-on-year to ₹6.17 crore. The net profit margin stood at -3.6%, a sharp fall from 3.5% in the same quarter last year.
Why did KMS Medisurgi's total expenses rise 16% QoQ in Q2 FY27?
KMS Medisurgi's total expenses rose sharply due to higher depreciation and employee costs. Scanx.trade reported a 77% surge in depreciation in FY26 from capital additions of ₹1.72 crore for a new coating line. This fixed-cost increase occurred despite only a 10.4% sequential revenue recovery.
What caused the 37% YoY increase in depreciation for KMS Medisurgi in Q2 FY27?
The increase in depreciation for KMS Medisurgi stems from significant capital expenditure. According to Scanx.trade, the company added ₹1.72 crore in plant and machinery in FY26, primarily for a new coating line. This investment has led to a sustained rise in depreciation charges, pressuring margins.
What guidance did KMS Medisurgi management provide for FY27 after the Q2 loss?
KMS Medisurgi's management did not provide specific revenue or profit guidance for FY27 following the Q2 results. Analysis from MCapital estimated full-year revenue could decline 2.5-7.4% and net profit could fall 72-88% compared to FY26, based on the weak first-half performance.
What is the status of KMS Medisurgi's working capital and cash flow?
KMS Medisurgi has minimal debt, with a debt-to-equity ratio of 0.1. Analysis from Newboard.in notes the business generated more cash from operations than operating profit in FY26, and debtor days have improved. This suggests working capital management is not the immediate pressure point.
Is KMS Medisurgi undertaking any significant capacity expansion currently?
Yes, KMS Medisurgi recently completed a capacity expansion. The company added a new coating line during FY26, which its annual report stated would nearly double capacity. However, this has led to higher depreciation costs before contributing to sales growth.
How did KMS Medisurgi's stock price react to the Q2 FY27 results announcement?
KMS Medisurgi's stock price fell nearly 5% following the Q2 FY27 results announcement on November 14, 2026. Data from Marketsmojo.com shows the share price declined from ₹139.40 to ₹132.45, reflecting a negative market reaction to the reported loss and weak outlook.
Did KMS Medisurgi's Q2 FY27 results beat or miss analyst estimates?
KMS Medisurgi's Q2 results were viewed as a clear miss. Analysis platform MCapital labeled the impact 'very negative,' noting the near wipe-out of H1 profit points to much lower full-year earnings. The stock's immediate 5% drop confirms the results disappointed market expectations.
Have any institutional investors changed their stake in KMS Medisurgi recently?
No, institutional ownership in KMS Medisurgi remains negligible. Data from The Economic Times shows Foreign Institutional Investors (FII) and Domestic Institutional Investors (DII) held 0.00% stake as of September 2026. Promoters hold a steady 74.42% of the company.
KMS Medisurgi Q2 profit drop?
KMS Medisurgi's profit turned into a loss in Q2 FY27. The company reported a net loss of ₹0.22 crore for the quarter ended September 2026, a severe drop from a net profit of ₹0.23 crore in the same quarter last year, driven by higher costs and lower sales.
KMS Medisurgi H1 FY27 results?
For the half-year ended September 2026, KMS Medisurgi reported a net loss of ₹0.22 crore on revenue of ₹6.17 crore. This compares to a net profit of ₹0.23 crore on revenue of ₹6.62 crore in H1 FY26, indicating a sharp deterioration in profitability.
KMS Medisurgi auditor report concerns?
KMS Medisurgi's auditor, H H Dedhia & Associates, raised concerns in its limited review report. As reported by ForgeUp, the auditor noted a departure from accounting standards on post-employment benefits and could not ascertain the value of closing stock due to a pending reconciliation.